Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 205,183,928 papers from all fields of science
Search
Sign In
Create Free Account
ARC 1779
Known as:
ARC-1779
, ARC1779
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
2 relations
Broader (1)
Aptamers, Nucleotide
ULvWF Multimer-targeting Agent ARC1779
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Review
2012
Review
2012
Initial experience from a double‐blind, placebo‐controlled, clinical outcome study of ARC1779 in patients with thrombotic thrombocytopenic purpura
S. Cataland
,
F. Peyvandi
,
+10 authors
P. Knoebl
American journal of hematology
2012
Corpus ID: 19324789
quency counts and percentages. Continuous variables were summarized using one or more of the following: mean, standard deviation…
Expand
Highly Cited
2012
Highly Cited
2012
The anti-von Willebrand factor aptamer ARC1779 increases von Willebrand factor levels and platelet counts in patients with type 2B von Willebrand disease.
P. Jilma-Stohlawetz
,
P. Knöbl
,
J. Gilbert
,
B. Jilma
Thrombosis and haemostasis
2012
Corpus ID: 4529602
Blockade of hyperactive von Willebrand factor (VWF) by ARC1779 blunted the platelet drop induced by desmopressin in patients with…
Expand
Highly Cited
2011
Highly Cited
2011
A dose ranging phase I/II trial of the von Willebrand factor inhibiting aptamer ARC1779 in patients with congenital thrombotic thrombocytopenic purpura.
P. Jilma-Stohlawetz
,
J. Gilbert
,
M. E. Gorczyca
,
P. Knöbl
,
B. Jilma
Thrombosis and haemostasis
2011
Corpus ID: 4481380
Congenital thrombotic thrombocytopenic purpura (TTP) is a very rare but potentially life-threatening disorder. This phase I/II…
Expand
Highly Cited
2011
Highly Cited
2011
Inhibition of von Willebrand factor by ARC1779 in patients with acute thrombotic thrombocytopenic purpura.
P. Jilma-Stohlawetz
,
M. E. Gorczyca
,
B. Jilma
,
J. Siller-Matula
,
J. Gilbert
,
P. Knöbl
Thrombosis and haemostasis
2011
Corpus ID: 44575055
Thrombotic thrombocytopenic purpura (TTP) can cause severe organ damage due to enhanced platelet aggregation by ultra-large von…
Expand
Review
2010
Review
2010
Pharmacokinetic, pharmacodynamic and clinical profile of novel antiplatelet drugs targeting vascular diseases
J. Siller-Matula
,
Julia Krumphuber
,
B. Jilma
British journal of pharmacology
2010
Corpus ID: 25543207
Platelet inhibitors are the mainstay treatment for patients with vascular diseases. The current ‘gold standard’ antiplatelet…
Expand
Highly Cited
2010
Highly Cited
2010
A randomised pilot trial of the anti-von Willebrand factor aptamer ARC1779 in patients with type 2b von Willebrand disease.
B. Jilma
,
P. Paulinska
,
P. Jilma-Stohlawetz
,
J. Gilbert
,
R. Hutabarat
,
P. Knöbl
Thrombosis and haemostasis
2010
Corpus ID: 20347362
Desmopressin aggravates thrombocytopenia in type 2B von Willebrand disease (VWF type 2B) by release of large and hyper-adhesive…
Expand
Highly Cited
2009
Highly Cited
2009
Inhibition of von Willebrand factor‐mediated platelet activation and thrombosis by the anti‐von Willebrand factor A1‐domain aptamer ARC1779
J. Diener
,
H. A. DANIEL LAGASSÉ
,
+6 authors
R. Schaub
Journal of thrombosis and haemostasis : JTH
2009
Corpus ID: 22350886
Summary. Background: von Willebrand factor (VWF) has a role in both hemostasis and thrombosis. Platelets adhere to damaged…
Expand
Highly Cited
2009
Highly Cited
2009
Anti–von Willebrand factor aptamer ARC1779 for refractory thrombotic thrombocytopenic purpura
P. Knöbl
,
B. Jilma
,
J. Gilbert
,
R. Hutabarat
,
Patricia G. Wagner
,
P. Jilma-Stohlawetz
Transfusion
2009
Corpus ID: 23602274
BACKGROUND: Plasma exchange is the main therapy for thrombotic thrombocytopenic purpura (TTP). No treatments other than plasma…
Expand
Review
2008
Review
2008
Von Willebrand Factor in Cardiovascular Disease: Focus on Acute Coronary Syndromes
A. Spiel
,
J. Gilbert
,
B. Jilma
Circulation
2008
Corpus ID: 308486
von Willebrand factor (VWF) plays a pivotal role in platelet adhesion and aggregation at sites of high shear rates (eg, in…
Expand
Highly Cited
2007
Highly Cited
2007
First-in-Human Evaluation of Anti–von Willebrand Factor Therapeutic Aptamer ARC1779 in Healthy Volunteers
J. Gilbert
,
T. Defeo-Fraulini
,
+7 authors
R. Schaub
Circulation
2007
Corpus ID: 23102907
Background— ARC1779 is a therapeutic aptamer antagonist of the A1 domain of von Willebrand Factor (vWF), the ligand for receptor…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
,
Terms of Service
, and
Dataset License
ACCEPT & CONTINUE